NxStage Medical, Inc. (NASDAQ:NXTM) insider Robert S. Brown sold 3,054 shares of the stock in a transaction on Wednesday, February 8th. The stock was sold at an average price of $27.61, for a total transaction of $84,320.94. Following the transaction, the insider now directly owns 19,763 shares in the company, valued at $545,656.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) opened at 28.38 on Monday. The company’s market cap is $1.84 billion. The company has a 50 day moving average of $26.92 and a 200 day moving average of $24.86. NxStage Medical, Inc. has a 1-year low of $13.49 and a 1-year high of $28.71.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: NxStage Medical, Inc. (NXTM) Insider Sells $84,320.94 in Stock” was first published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this news story on another site, it was copied illegally and reposted in violation of U.S. and international copyright legislation. The correct version of this news story can be read at http://sleekmoney.com/insider-selling-nxstage-medical-inc-nxtm-insider-sells-84320-94-in-stock/1657866.html.
Several equities analysts have commented on NXTM shares. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research report on Thursday, November 3rd. Canaccord Genuity reissued a “buy” rating and set a $28.00 target price on shares of NxStage Medical in a research report on Thursday, November 3rd. Northland Securities set a $35.00 target price on shares of NxStage Medical and gave the stock a “buy” rating in a research report on Friday, December 16th. Finally, Jefferies Group LLC upped their price target on shares of NxStage Medical to $38.00 and gave the company a “buy” rating in a report on Monday, February 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $29.67.
A number of institutional investors have recently added to or reduced their stakes in the company. Elkfork Partners LLC bought a new position in NxStage Medical during the fourth quarter worth about $1,324,000. Marshall Wace LLP bought a new position in NxStage Medical during the fourth quarter worth about $5,976,000. Oxford Asset Management boosted its position in NxStage Medical by 14.2% in the fourth quarter. Oxford Asset Management now owns 82,120 shares of the medical device company’s stock worth $2,152,000 after buying an additional 10,242 shares in the last quarter. State Street Corp boosted its position in NxStage Medical by 2.2% in the fourth quarter. State Street Corp now owns 1,208,700 shares of the medical device company’s stock worth $31,678,000 after buying an additional 26,359 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in NxStage Medical during the fourth quarter worth about $449,000. Institutional investors and hedge funds own 97.26% of the company’s stock.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/insider-selling-nxstage-medical-inc-nxtm-insider-sells-84320-94-in-stock/1657866.html
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.